GMAB

GenmabCPSE:GMAB Stock Report

Market Cap

kr.176.5b

7D

-3.0%

1Y

11.0%

Updated

18 Sep, 2021

Data

Company Financials +
GMAB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance1/6
Financial Health6/6
Dividends0/6

GMAB Overview

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.

Genmab Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Genmab
Historical stock prices
Current Share Pricekr.2,700.00
52 Week Highkr.1,901.50
52 Week Lowkr.3,100.00
Beta0.60
1 Month Change-9.06%
3 Month Change-0.81%
1 Year Change11.02%
3 Year Change157.14%
5 Year Change136.22%
Change since IPO1,058.80%

Recent News & Updates

Jul 15
Are Investors Undervaluing Genmab A/S (CPH:GMAB) By 35%?

Are Investors Undervaluing Genmab A/S (CPH:GMAB) By 35%?

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Genmab A/S ( CPH:GMAB...

May 23
With EPS Growth And More, Genmab (CPH:GMAB) Is Interesting

With EPS Growth And More, Genmab (CPH:GMAB) Is Interesting

Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...

Shareholder Returns

GMABDK BiotechsDK Market
7D-3.0%-3.2%-0.1%
1Y11.0%11.4%32.7%

Return vs Industry: GMAB matched the Danish Biotechs industry which returned 11.4% over the past year.

Return vs Market: GMAB underperformed the Danish Market which returned 32.7% over the past year.

Price Volatility

Is GMAB's price volatile compared to industry and market?
GMAB volatility
GMAB Beta0.60
Industry Beta0.70
Market Beta1

Stable Share Price: GMAB is not significantly more volatile than the rest of Danish stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: GMAB's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19991,029Jan van de Winkelhttps://www.genmab.com

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies.

Valuation

Is Genmab undervalued compared to its fair value and its price relative to the market?

39.0%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: GMAB (DKK2700) is trading below our estimate of fair value (DKK4428.7)

Significantly Below Fair Value: GMAB is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: GMAB is poor value based on its PE Ratio (70.2x) compared to the European Biotechs industry average (25.5x).

PE vs Market: GMAB is poor value based on its PE Ratio (70.2x) compared to the Danish market (15.6x).


Price to Earnings Growth Ratio

PEG Ratio: GMAB is poor value based on its PEG Ratio (2.2x)


Price to Book Ratio

PB vs Industry: GMAB is overvalued based on its PB Ratio (8.7x) compared to the DK Biotechs industry average (6.9x).


Future Growth

How is Genmab forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?

32.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GMAB's forecast earnings growth (32.3% per year) is above the savings rate (0.1%).

Earnings vs Market: GMAB's earnings (32.3% per year) are forecast to grow faster than the Danish market (8.9% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: GMAB's revenue (22.7% per year) is forecast to grow faster than the Danish market (7.4% per year).

High Growth Revenue: GMAB's revenue (22.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GMAB's Return on Equity is forecast to be low in 3 years time (18.7%).


Past Performance

How has Genmab performed over the past 5 years?

37.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GMAB has a large one-off gain of DKK685.0M impacting its June 30 2021 financial results.

Growing Profit Margin: GMAB's current net profit margins (34.3%) are lower than last year (54.7%).


Past Earnings Growth Analysis

Earnings Trend: GMAB's earnings have grown significantly by 37.8% per year over the past 5 years.

Accelerating Growth: GMAB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: GMAB had negative earnings growth (-55.6%) over the past year, making it difficult to compare to the Biotechs industry average (19.9%).


Return on Equity

High ROE: GMAB's Return on Equity (12.4%) is considered low.


Financial Health

How is Genmab's financial position?


Financial Position Analysis

Short Term Liabilities: GMAB's short term assets (DKK20.3B) exceed its short term liabilities (DKK1.4B).

Long Term Liabilities: GMAB's short term assets (DKK20.3B) exceed its long term liabilities (DKK880.0M).


Debt to Equity History and Analysis

Debt Level: GMAB is debt free.

Reducing Debt: GMAB has not had any debt for past 5 years.

Debt Coverage: GMAB has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: GMAB has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Genmab current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GMAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GMAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GMAB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GMAB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GMAB's dividend in 3 years as they are not forecast to pay a notable one for the Danish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

Jan van de Winkel (60 yo)

11.25yrs

Tenure

kr.37,300,000

Compensation

Dr. Jan G. J. van de Winkel, Ph D., serves as a Member of Advisory board at Thuja Capital Management B.V. Dr. van de Winkel served as a Member of Scientific Advisory Board.He is a Co-Founder of Genmab A/S...


CEO Compensation Analysis

Compensation vs Market: Jan's total compensation ($USD5.89M) is above average for companies of similar size in the Danish market ($USD3.60M).

Compensation vs Earnings: Jan's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: GMAB's management team is considered experienced (3.5 years average tenure).


Board Members

Experienced Board: GMAB's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Genmab A/S's employee growth, exchange listings and data sources


Key Information

  • Name: Genmab A/S
  • Ticker: GMAB
  • Exchange: CPSE
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr.176.531b
  • Shares outstanding: 65.38m
  • Website: https://www.genmab.com

Number of Employees


Location

  • Genmab A/S
  • Kalvebod Brygge 43
  • Copenhagen
  • Capital Region of Denmark
  • 1560
  • Denmark

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/18 17:03
End of Day Share Price2021/09/17 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.